The combination of bevacizumab with chemotherapy is more beneficial in the metastatic setting rather than in the adjuvant setting for the treatment of HER2-negative breast cancer-a commentary on the E5103 randomized phase III clinical study

Transl Cancer Res. 2019 Mar;8(Suppl 2):S94-S96. doi: 10.21037/tcr.2018.10.17.

Authors

Giandomenico Roviello¹, Daniele Generali^{2

3}, Navid Sobhani^{2

3}

Affiliations

¹ Division of Medical Oncology, Department of Oncology, University Hospital of Trieste, Trieste, Italy.
² Breast Cancer Unit and Translational Research Unit, ASST Cremona, Cremona, Italy.
³ Department of Medical, Surgery and Health Sciences, University of Trieste, Trieste, Italy.

No abstract available

Publication types

Editorial
Comment